Loading...
•
Mar 26, 2022
Henry Schein Q1 2022 Earnings Report
Henry Schein reported record first-quarter financial results, driven by strong performance in dental and medical sales.
Key Takeaways
Henry Schein reported record first-quarter financial results with net sales of $3.2 billion, an increase of 8.7% compared to the first quarter of 2021. GAAP diluted EPS was $1.30, compared to $1.16 in the first quarter of 2021. The company affirmed its full-year 2022 GAAP diluted EPS guidance of $4.75 to $4.91.
Total first-quarter net sales reached $3.2 billion, up 8.7% compared to Q1 2021.
GAAP diluted EPS was $1.30, compared to $1.16 in Q1 2021.
Global Dental sales increased by 2.2% compared to the prior-year period.
Global Medical sales increased by 18.3% compared to the comparable period last year.
Henry Schein
Henry Schein
Henry Schein Revenue by Segment
Henry Schein Revenue by Geographic Location
Revenue by Segment
Global Dental Revenue
CapyFin.comGlobal Medical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Distribution and Value-Added Services Revenue
CapyFin.comInternational Distribution and Value-Added Services Revenue
CapyFin.com Forward Guidance
Henry Schein affirms guidance for 2022 GAAP diluted EPS to be $4.75 to $4.91 and full year sales growth is expected to be approximately 5% to 8% over 2021.
Positive Outlook
- 2022 GAAP diluted EPS attributable to Henry Schein, Inc. is expected to be $4.75 to $4.91.
- Reflects growth of 7% to 10% compared with 2021 GAAP diluted EPS of $4.45.
- Reflects growth of 5% to 9% compared with 2021 non-GAAP diluted EPS of $4.52.
- 2022 full year sales growth is expected to be approximately 5% to 8% over 2021.
- Guidance assumes that foreign currency exchange rates will remain generally consistent with current levels and end markets will remain stable.
Challenges Ahead
- Sales growth primarily reflects the latest foreign exchange rates and a decrease in sales of COVID-19 test kits.
- Guidance does not include the impact of future share repurchases.
- Guidance does not include potential future acquisitions or restructuring expenses, if any.
- Guidance assumes that there are no material adverse market changes associated with COVID-19.
- Forward-looking statements are subject to risks and uncertainties.
Revenue & Expenses
Visualization of income flow from segment revenue to net income